New at Santen

Article

Dr Naveed Shams has been appointed as the new vice president of clinical affairs at Santen Pharmaceutical Co., Ltd.

Dr Naveed Shams has been appointed as the new vice president of clinical affairs at Santen Pharmaceutical Co., Ltd.

“Dr. Shams is a highly respected scientist and brings an expertise in developing and commercializing ophthalmic drugs, ” said Santen Chief Operating Officer, Aki Tsujimura. “His insights in this area will prove invaluable, as he has a wealth of experience in basic research, drug discovery, ophthalmic formulations, and drug delivery. ”

Dr Shams received his medical degree from Dow Medical College in Karachi, Pakistan, and his Ph.D. from the University of South Carolina in microbiology and immunology. He completed fellowships in cornea and external diseases at Harvard Medical School and histocompatibility and immunogenetics at Massachusetts General Hospital. He was formerly on faculty at Schepen's Eye Research Institute and the Department of Ophthalmology at Harvard Medical School.

His career in drug development is extensive and he has played a role in bringing Zaditen, Rescula and Lucentis to market.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.